256934-39-1

A specific CB2-specific agonist that inhibits forskolin-stimulated cAMP production in CB2-transfected cells. It reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity and thus may lead to new therapies for hypertension, inflammation, and pain. Controlled Substance.

ChEBI: HU-308 is a carbobicyclic compound that is bicyclo[3.1.1]hept-2-ene which is substituted by a hydroxymethyl group at position 2, a 2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl group at position 4, and two methyl groups at position 6 (the 1S,4S,5S stereoisomer). A highly selective and effective cannabinoid type-2 agonist and the enantiomer of HU-433. It has a role as a CB2 receptor agonist, an anti-inflammatory agent, a bone density conservation agent, an apoptosis inhibitor and an antihypertensive agent. It is a bridged compound, a carbobicyclic compound, an aromatic ether, a synthetic cannabinoid and a primary allylic alcohol.

Potent and selective CB 2 receptor agonist (K i values are 22.7 nM and > 10 μ M for CB 2 and CB 1 receptors respectively, EC 50 = 5.57 nM). Displays antiallodynic activity in the rat hindpaw incision model of postoperative pain.

Store at -20°C